Ian Dunham | Scientific Director, Open Targets
European Bioinformatics Institute

Ian Dunham, Scientific Director, Open Targets, European Bioinformatics Institute


BioData West- NASA Ames Satellite Conference & Workshops @ 13:30

DATATHON ON OPEN TARGETS: In partnership with EMBL- EBI and Sanger Institute

Part 1: Educating on the open targets platform
Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.
Visit the Open Targets Platform which provides an integration of public domain data to enable target identification and prioritisation.
Generating and interpreting the data required to identify a good drug target demands a diverse set of skills, backgrounds, evidence types and technologies, which do not exist today in any single entity. Open Targets brings together expertise from four complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed.
Our goals are to:
  • Systematically find the best targets to safely & effectively treat disease
  • Help others find good targets
  • Get those targets adopted into drug discovery pipelines
We currently focus on oncology, immunology and neurodegeneration through an R&D framework that can be applied to all aspects of human disease

Instructors and Leaders:
Ian Dunham, Scientific Director, Open Targets, EMBL-EBI
Denise Carvalho-Silva, Scientific Outreach Lead, EMBL-EBI
Matthew Nelson, Head of Genetics, GSK
Mark Hurle, Director of Computational Biology, GSK
Gautier Koscielny, Scientific Director, Open Targets, GSK
Afshin Beheshti, Bioinformatician and Data Analyst, NASA Genelab

Part 2: Advance module

Integrating your expertise and AI approaches into the Open Targets platform

back to speakers